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Abstract Large cell neuroendocrine carcinoma (LCNEC)
of the lung is categorized as a variant of large cell carci-
nomas, and LCNEC tumors display biological behaviors
resembling those of small cell lung carcinomas and features
of high-grade neuroendocrine tumors. Because patients
with LCNEC have a poor prognosis, surgery alone is not
sufficient. Multimodality therapies, including adjuvant
chemotherapy, appear promising for improved prognosis in
patients with LCNEC. In this review article, we discuss
treatment options for patients with LCNEC of the lung.
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Introduction
In 1980, pulmonary neuroendocrine tumors were catego-
rized as typical carcinoids, atypical carcinoids, or small cell
lung carcinoma (SCLC) [1]. Travis et al. [2] proposed that
large cell neuroendocrine carcinoma (LCNEC) should
constitute a new category and reported that the prognosis of
LCNEC falls between those of atypical carcinoids and
SCLC. The World Health Organization [3] categorized
LCNEC as non-SCLC (NSCLC). Currently, LCNEC is
classified as a variant of large cell carcinomas; however,
the clinical and biological characteristics of LCNEC are
similar to those of SCLC. Therefore, there is still no
consensus on the treatment strategy for LCNEC [4]. In this
review article, we focus on treatment strategies for patients
with LCNEC.
Biological features of LCNEC
Several reports [5–7] revealed that the clinical behavior,
morphology, and prognosis of LCNEC were similar to those
of SCLC, even though there might be several clinicopath-
ological differences between SCLC and LCNEC in
peripheral, small-sized, high-grade neuroendocrine tumors
[8]. Although Varlotto et al. [9] obtained and evaluated data
on LCNEC from the Surveillance, Epidemiology, and End
Results Program to show that the clinical, histopathologic,
and biologic features of LCNEC were more similar to those
of large cell carcinoma than SCLC, a central pathological
review by an expert panel was necessary to confirm the
diagnosis, a requisite lacking in the report by Varlotto et al.
[10, 11]. Cytomorphologically, LCNEC shows character-
istic arrangements, such as palisading or rosettes with
necrosis [12]. Morphometric analysis revealed significantly
different features between LCNEC and classic large cell
carcinomas. Iyoda et al. [13] showed that LCNEC had
significantly higher expression rates of Bcl-2 and the Ki-67
labeling index than did classic large cell carcinoma. These
results revealed that the cytological and biological features
of LCNEC were different from those of classic large cell
carcinoma. Jones et al. [14] examined the gene expression
profiles of LCNEC, SCLC, adenocarcinoma, and normal
lung using microarray analysis, which was unable to dis-
tinguish LCNEC from SCLC. Using the telomeric repeat
amplification protocol assay, Zaffaroni et al. [15] reported
that almost all LCNEC tumors showed telomerase activity
comparable to that of SCLC.
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On the other hand, Nitadori et al. [16] indicated that the
expression of CK7, CK18, E-cadherin, and b-catenin is
more characteristic of LCNEC than of SCLC, suggesting
that LCNEC and SCLC are separate entities. Ullmann et al.
[17] examined comparative genomic hybridization (CGH)
for LCNEC and SCLC and showed that there were dif-
ferences between the two in the expression from chromo-
somal regions 3q, 6p, 10q, 16q, and 17p. Peng et al. [18]
evaluated array-based CGH for LCNEC and SCLC and
reported differences in expression at 2q, 3p, 4q, and 6p,
even though LCNEC and SCLC had multiple characteristic
chromosomal alterations in common. Hiroshima et al. [19]
examined loss of heterozygosity (LOH) in microsatellite
markers and methylation of the p16 gene in LCNEC,
SCLC, and classic large cell carcinoma, and they reported
that the LOH patterns of LCNEC resembled those of
SCLC, even though LCNEC was also similar to classic
large cell carcinoma with regard to p16 gene methylation.
While many clinicopathological features of LCNEC were
similar to those of SCLC, some of the biological behaviors
of LCNEC differed from those of SCLC.
Surgery for patients with LCNEC
Because most LCNECs have been diagnosed postopera-
tively by surgical specimens, many reports on LCNEC
have referred to surgical cases, of which the majority [6,
20–27] revealed that patients with LCNEC had poor
prognoses with five-year survival rates of 15–57 %.
Moreover, even patients with pathological stage I LCNEC
have had poor prognoses, with five-year survival rates of
27–67 % [22–26]. Iyoda et al. [28] compared the prognoses
of LCNEC patients with pathological stage IA with those
of patients with adenocarcinomas or squamous cell carci-
nomas of the same stage, and they revealed that the five-
year survival rate of the LCNEC patients was 54.5 versus
89.3 % for the adenocarcinoma or squamous cell carci-
noma patients. In LCNEC patients with complete resection,
many recurrent tumors were observed as distant metastases
[29, 30]. Therefore, surgery alone is not sufficient to treat
patients with LCNEC, and subsequent adjuvant therapy
may be necessary [4, 31, 32]. In 2001, Iyoda et al. [33]
reported that postoperative adjuvant chemotherapy was
effective in patients with LCNEC. Veronesi et al. [23]
reported that 12 of 15 LCNEC cases administered induc-
tion chemotherapy were responsive (a partial response in
11 patients, a complete response in one patient) and that
stage I LCNEC patients with induction or adjuvant che-
motherapy tended to have a better survival than those
without such therapies (p = 0.077). In 2005, in a retro-
spective study by Rossi et al. [25] adjuvant chemotherapy
with CDDP?VP-16 was reported to be effective for
patients with LCNEC. Iyoda et al. [34] started a prospec-
tive study of adjuvant chemotherapy in patients with
LCNEC in 2000, and they selected CDDP?VP-16 as the
chemotherapeutic regimen because the clinicopathologic
and biological features of LCNEC are very similar to those
of SCLC. They reported in 2006 that patients with adjuvant
chemotherapy after complete surgical resection had a good
prognosis compared with the historical control group.
Sarkaria et al. [35] reported that LCNEC had a high
response rate to platinum-based neoadjuvant chemother-
apy, and that resected advanced-stage patients receiving
combination neoadjuvant and/or adjuvant chemotherapy
may have a survival advantage. They suggested that these
therapies should be considered in resectable patients with
LCNEC.
Recently, many studies have reported that perioperative
chemotherapy may be beneficial in patients with resected
LCNEC [32, 36, 37]. Tanaka et al. [38] performed a unique
study and suggested that perioperative chemotherapy might
benefit the survival of patients with LCNEC if the tumors
are not immunoreactive to the three neuroendocrine
markers evaluated.
Which agents are better for treatment of LCNEC
patients: SCLC-based versus non-SCLC-based
regimens?
When using chemotherapy, we have to consider whether to
use SCLC-based or non-SCLC-based regimens for LCNEC
patients, since LCNEC is currently classified as non-SCLC,
even though the clinical and biological characteristics of
LCNEC are similar to those of SCLC.
Sun et al. [39] revealed that the response rate to platinum-
based chemotherapy was 60 %, whereas the response rate to
non-platinum-based chemotherapy was 11 %. Moreover,
they examined whether advanced LCNEC should be treated
similarly to SCLC versus non-SCLC with respect to che-
motherapeutic regimens, and they concluded that advanced
LCNEC could be treated appropriately in a manner similar
to SCLC rather than NSCLC. Igawa et al. [40] reported that
the effectiveness of chemotherapy for unresectable LCNEC
was comparable to that for extended disease SCLC. Tokito
et al. [41] reported that the response rate for SCLC-based
chemotherapy was 70 % in patients with LCNEC. Shimada
et al. [42] suggested that the overall response rate to initial
chemotherapy or chemoradiotherapy and the survival out-
comes of high-grade neuroendocrine carcinoma-probable
LCNEC were comparable to those of SCLC, even though
the efficacy of second-line chemotherapy might differ
between LCNEC and SCLC. Yamazaki et al. [43] reported
that the response rate of LCNEC to cisplatin-based che-
motherapy was comparable with that of SCLC.
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Surgical indication for patients with LCNEC
Treut et al. [44] performed a multicenter phase II study of
cisplatin–etoposide chemotherapy for stage IIIB or IV
LCNEC patients, and they concluded that the outcome of
advanced LCNEC patients treated with cisplatin–etoposide
doublet chemotherapy was poor, comparable with that of
patients with advanced SCLC, with an 8-month median
overall survival. Their study revealed that the multi-insti-
tutional trials on LCNEC, especially on treatments such as
chemotherapy, were necessary to have the centralized
pathologist review because their study reclassified 11
(27.5 %) of 40 LCNEC patients into 9 as SCLC, 1 as
undifferentiated non-SCLC, and 1 as atypical carcinoid.
These difficulties may also affect the result of clinical trials
using adjuvant chemotherapy for LCNEC patients. Niho
et al. [45] performed combination chemotherapy with iri-
notecan and cisplatin in patients with advanced LCNEC and
revealed that the response rate was 46.7 % in the LCNEC
group. They concluded that combination chemotherapy with
irinotecan and cisplatin was an active regimen in patients
with LCNEC, although the response rate and the overall
survival period in LCNEC patients were inferior to those of
SCLC patients. Patients with advanced-stage LCNEC had a
poor prognosis because they could not always achieve a
complete response. Although there were high response rates
for platinum-based and SCLC-based chemotherapies,
almost all patients had only partial responses. Patients with
LCNEC may not be able to expect complete responses with
platinum-based and SCLC-based chemotherapies compared
with SCLC patients, even though these chemotherapies are
as effective as adjuvant treatment after removing tumors.
The indication for surgery is limited to stage I in patients
with SCLC, however, surgery with adjuvant chemotherapy
may achieve satisfactory results in terms of survival in
regard to surgical indications for patients with not only
stage I but also stage II/III in LCNEC [46]. Iyoda et al. [29]
reported that platinum-based adjuvant chemotherapy after
surgery might be useful for preventing recurrence in
patients with LCNEC. Therefore, surgical indications for
patients with LCNEC may not be limited to clinical stage I
cases, and surgery with adjuvant chemotherapy should be
attempted for resectable LCNEC.
New treatments for LCNEC
Many reports revealed that platinum-based and SCLC-
based chemotherapies were effective for patients with
LCNEC. However, those results were not enough to
improve the prognoses of patients with LCNEC, especially
those with advanced stages. Therefore, we need to discover
new treatments for patients with LCNEC.
As for new chemotherapeutic agents, Kenmotsu et al.
[47] reported that nedaplatin plus irinotecan was effective
and safe for patients with LCNEC. Yoshida et al. [48]
studied the effectiveness of amrubicin monotherapy in
patients with previously treated advanced LCNEC, for
whom they showed that amrubicin was potentially active,
yielding an objective response rate of 27.7 %.
With molecular targeted therapies, De Pas et al. [49]
reported a case of LCNEC with EGFR mutation, which had
a dramatic response to gefitinib. Kozuki et al. [32] also
reported a case with a partial response to gefitinib. Other
authors [50–52] reported cases of LCNEC with EGFR
mutation, but only a few [51, 53]. Even though few patients
have EGFR mutations, EGFR-TKI may be an optimal
treatment for certain patients with LCNEC. Filosso et al.
[54] concluded that octreotide, which is used for the
treatment of carcinoid syndrome, was effective for patients
with LCNEC.
In experimental studies, Odate et al. [55] found that the
expression of tropomyosin-related kinase B and brain-
derived neurotrophic factor was significantly higher in
LCNEC than in SCLC, and they proposed that these two
genes might be potential targets in LCNEC. Iyoda et al.
[53] examined new markers for patients with LCNEC, and
they suggested a potential role for anti-VEGF, anti-c-KIT,
and possibly anti-HER2-targeted agents in the treatment of
LCNEC. Yokouchi et al. [56] reported successful treatment
with intravitreal injection of bevacizumab in LCNEC
patients with metastasis to the iris.
Treatments for patients with LCNEC originating
from other organs
The first report of LCNEC was in the lung, and most
reports have also referred to pulmonary LCNECs. How-
ever, we may be able to get important information
regarding treatment options for lung LCNEC from studies
on treatments for patients with LCNEC of other organs.
Kusafuka et al. [57] reported a trend toward recom-
mending primary chemotherapy and radiation, rather than
primary surgery with postoperative radiation/systemic
therapy, for patients with LCNEC in the head and neck,
based on the fact that LCNEC has extremely similar clinical
features, patterns and timing of spread, and prognosis as
those of small cell carcinomas, suggesting that treatment
should also be similar. Ose et al. [58] reported a case of
thymic LCNEC administered induction chemoradiation
therapy (three cycles of cisplatin/etoposide and 45 Gy of
hyperfractionated radiation) because of invasion to the
aortic arch and pulmonary trunk. Pathologic examination
revealed no viable cells in the resected tumor, and the patient
was alive 3 years later without recurrence. Tangjitgamol
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et al. [59] reported a case of LCNEC of the uterine cervix with
good response to primary chemotherapy of paclitaxel/carbo-
platin. Embry et al. [60] suggested that LCNEC of the cervix
was more aggressive with a poorer prognosis than squamous
cell carcinoma, and perioperative chemotherapy, platinum
with or without etoposide, improved survival of patients with
LCNEC of the cervix. Yoseph et al. [61] conducted a review
of more than 70 cases with LCNEC of the uterine cervix and
found that current multimodal strategies have been adapted
mainly from treatments used for neuroendocrine carcinomas
of the lung, even though no consensus had been reached as far
as an optimal treatment plan because of the rarity of cervical
LCNEC. Oberstein et al. [62] reported that gastric LCNEC is
a high-grade tumor with an aggressive course, and that
treatment with platinum-based chemotherapy might provide
clinical benefits. Evans et al. [63] reported seven cases with
prostate LCNEC, of which all six cases with complete follow-
up died from widespread metastases, and five of these six
cases were treated with platinum-based chemotherapy, with a
mean survival of 7 months from the time of the last course.
Shimono et al. [64] reported that multimodal treatment,
including surgery, chemotherapy with cisplatin and etopo-
side, and radiation therapy, achieved a good response and
long survival in a patient with LCNEC of the gallbladder.
Although we are beginning to understand the clinico-
pathological and biological features of patients with
LCNEC little by little, there is no consensus on treatment
in patients with lung LCNEC. We need large-scale trials in
order to reach a consensus; however, in the near future, we
may not be able to perform such trials because of the rarity
of LCNEC cases. Therefore, we should continue trying to
obtain useful information from several small-scale studies
as well as to evaluate new strategies, including molecular
targeted therapies, for patients with LCNEC.
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